Tags: Drug Discovery


Stepping Forward in Alzheimer’s Disease Research: A Combination Therapy Approach

Chief Medical Officer at Amylyx Pharmaceuticals gives a closer look at how far they have come in their recently expanded phase 2 clinical trial, supported in part by the ADDF, which is studying a combination approach to treating people with Alzheimer’s disease.


Alzheimer’s Drug Discovery Foundation Statement on Biogen Announcement to Plan FDA Filing of Aducanu

The Alzheimer’s Drug Discovery Foundation is encouraged by today’s announcement from Biogen of its plans to seek regulatory approval for aducanumab as a potential new treatment for Alzheimer’s disease, particularly for people living with the early stages of Alzheimer’s.


Alzheimer’s Drug Discovery Foundation Partners with Shionogi and Janssen Pharmaceuticals for its Dia

The Alzheimer’s Drug Discovery Foundation (ADDF) announced a partnership with Shionogi & Co., Ltd.  and Janssen Pharmaceuticals, Inc. as part of its  Diagnostics Accelerator, an initiative that aims to fast-track the development of novel biomarkers for the early detection of Alzheimer's disease and related dementias.


$3.2 Million in New Funding Focused on Biomarkers and Moving Toward New Therapies

These recent investments reflect the ADDF's commitment to advancing tools for early detection, with an emphasis on exploring the different pathologies associated with aging.


$7.1 Million in New Funding Illustrates the ADDF's Strong Support of a Diverse Pipeline

The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.


New Investments Fund Research Ranging from Novel Treatments for Postoperative Cognitive Dysfunction

The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy.


$2.5 Million in New Funding Exemplifies ADDF’s Strategy

We announce $2.5 million in new funding, which reflects the comprehensive nature of our strategy to prevent and treat Alzheimer’s disease. 


ADDF and Harrington Discovery Institute Invite Applications for 2018 ADDF-Harrington Scholar Award

Harrington Discovery Institute and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a request for proposals for the 2018 ADDF-Harrington Scholar Award.


Funding Supports New Approaches to Treat Multiple Types of Dementia

The ADDF announces two investments in programs targeting mitochondria and the progranulin gene.